Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972711 | 0.87 | CALM1 (0.69) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL5534889 | 0.81 | HTR2A (0.63) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL132297 | 0.81 | HSPA5 (0.38) | CALM1HIF1A | |
| SCHEMBL5541602 | 0.78 | HTR1A (0.48) | HTR2AHPGDSMN1; SMN2ALOX15HSD17B10 | |
| SCHEMBL1287474 | 0.75 | CALM1 (0.52) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL11475889 | 0.75 | HTR2A (0.56) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL1773099 | 0.75 | HTR2A (0.56) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL3821433 | 0.75 | HTR2A (0.56) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL695542 | 0.75 | HTR2A (0.56) | HTR2ACALM1BCL2BCL2L1ALOX5 | |
| SCHEMBL6548117 | 0.75 | HTR2A (0.56) | HTR2ACALM1BCL2BCL2L1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021253013-A2 | MODULATORS OF E3 LIGASES | REKINDLE THERAPEUTICS INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| CN-112118827-A | Foaming cleanser composition containing nonpolar oil and amphiphilic polymer | 路博润先进材料公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| EP-1866319-A1 | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-19 | — | — | EP | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5338655-A | Using a spectral sensitizing dyes | KONICA CORPORATION (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0533033-A1 | Method for manufacturing a silver halide emulsion | KONICA CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-5015563-A | Comprising silver halide grains formed in the presence of the mercapto or azaindene compound, a coupler and a high-boiling organic solvent (dielectric of <6); antifogging agents | KONICA CORPORATION (JP) | 1991-05-14 | — | — | US | disclosed |
| EP-0256781-A2 | Silver halide light-sensitive color photographic material suitable for rapid processing | KONICA CORPORATION (JP) | 1988-02-24 | — | — | EP | disclosed |
| US-4710454-A | CONTAINING PHOSPHONIC ACID AND POLYACRYLIC DERIVATIVE | AGFA-GEVAERT AKTIENGESELLSCHAFT, A CORP. OF GERMANY (DE) | 1987-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HTR2A 1158/4885CALM1 2210/4885BCL2 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.